Highlights:

  • Sonic Healthcare (ASX:SHL) shares were trading at AUD 21.88, down 7.13% during the afternoon Trading session on 20 August 2026.
  • FY2026 Revenue increased 13% to AUD 10.867 billion, with organic revenue growth of 5%.
  • Underlying EBITDA increased 11% to AUD 1.933 billion, while underlying net profit increased 17% to AUD 621 million.
  • The company completed the LADR Laboratory Group Acquisition and reported integration progress with synergies on schedule.
  • Sonic Healthcare maintained its progressive Dividend policy, increasing total FY2026 dividends by 1 cent to AUD 1.08 per share.

Sonic Healthcare Limited (ASX:SHL) has reported its FY2026 financial results, delivering revenue growth, higher earnings, acquisition integration progress, and continued Investment in digital and operational initiatives.

Sonic Healthcare shares were trading at AUD 21.88, down 7.13% during the afternoon trading session on 20 August 2026. Over the past year, the company’s shares remain down 23.87%. The company’s annual results highlighted growth across its global diagnostics operations, synergy realisation from acquisitions, and ongoing Capital management activities.

Sonic Healthcare operates medical diagnostics businesses across multiple countries and markets, providing pathology and related healthcare services globally.

FY2026 Revenue and Earnings Growth

Sonic Healthcare reported revenue of AUD 10.867 billion for FY2026, representing a 13% increase compared with the previous year.

The company achieved organic revenue growth of 5%, supported by growth across its diagnostics operations.

Underlying Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) increased 11% to AUD 1.933 billion, while statutory EBITDA increased 9% to AUD 1.882 billion.

Underlying net profit increased 17% to AUD 621 million, while statutory net profit increased 18% to AUD 608 million.

Underlying Earnings Per Share increased 14% to 125.6 cents, while statutory earnings per share increased 15% to 123.0 cents.

Acquisition Integration and Operational Initiatives

Sonic Healthcare said the LADR Laboratory Group acquisition has been completed, with integration progressing according to schedule.

The company also continued capturing synergies from recent acquisitions in Switzerland.

Management highlighted growth in advanced diagnostics, supported by the company’s medical brands and capabilities across multiple regions.

During FY2026, Sonic Healthcare also commenced a comprehensive operating review of its United States Business and launched digital and artificial intelligence transformation initiatives across its global operations.

Dividend Maintained Under Progressive Policy

Sonic Healthcare maintained its progressive dividend approach during FY2026.

The company increased its total dividend for the year by 1 cent to AUD 1.08 per share.

The dividend reflects the company’s approach of returning capital to shareholders while continuing investment in operational improvements, technology initiatives, and business growth.

Capital Management and Business Developments

Sonic Healthcare completed the sale and leaseback of its Brisbane hub laboratory as part of its capital management program.

The company said it continues to focus on disciplined capital allocation alongside investments in operational capabilities and technology.

CEO Dr Jim Newcombe said the FY2026 result reflected revenue growth, operational leverage, and synergy realisation from recent acquisitions.

He highlighted the company’s focus on organic growth, efficiency, innovation, and capital management while continuing to invest in future growth initiatives.

Global Diagnostics Platform and Future Focus

Sonic Healthcare operates across nine countries and 11 markets, serving more than 140 million patients annually.

The company highlighted three areas supporting its operating approach: scale and diversification, medical leadership, and operational execution.

Management said its priorities include continued organic growth, efficiency initiatives, digital infrastructure upgrades, and maintaining disciplined capital management.

The company employs approximately 47,000 people globally and continues to provide medical diagnostic services across its operating regions.

Investor Takeaway

Sonic Healthcare’s FY2026 results showed revenue and earnings growth, acquisition integration progress, and continued investment in digital and operational initiatives. The company achieved its underlying EBITDA guidance while maintaining its progressive dividend policy.

Investors may continue to monitor the company’s United States operating review, synergy realisation from acquisitions, advanced diagnostics growth, digital transformation initiatives, and broader healthcare market conditions.